RTTNews | Jul 15, 2021 10:21AM EDT

10:20 Thursday, July 15, 2021 (RTTNews.com) - Shares of Swiss clinical-stage pharmaceutical company NLS Pharmaceutics AG (NLSP) are climbing more than 4% Thursday morning.

NLS today said, the FDA has accepted its investigational new drug application (IND) for Quilience, the Company's lead drug candidate, for the treatment of narcolepsy.

The company plans to start Phase 2a study of Quilience in August 2021.

NLSP is at $3.13 currently. It has traded in the range of $2.06- $7.35 in the last one year.

Read the original article on RTTNews ( https://www.rttnews.com/3209435/nls-pharmaceutics-jumps-4-on-getting-fda-acceptance-for-its-quilience-ind.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved